BAP1-IN-1 is an inhibitor of the catalytic activity of BRCA1-associated protein 1 (BAP1), which is related to cancer and can be used to study cancer.

After 24 h treatment at a concentration of 0.1 μM, BAP1-IN-1 significantly affected BAP1-WT cells, altering the expression levels of 240 genes in them. Only 33 transcripts were affected in BAP1-KO cells.The changes in gene expression induced by BAP1-IN-1 were largely dependent on the functional status of the BAP1 protein. [1]

Administration of BAP1-IN-1 (50 mg/kg/day for 4 weeks) to mice by intravenous injection was effective in slowing down the progression of ASXL1 mutant leukemia and enhancing the survival rate of mice. [1]